Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: AIDS. 2013 Oct;27(0 1):S5–15. doi: 10.1097/QAD.0000000000000058

Table 2.

Hormonal Content, Delivery Route and Progestin Concentrations with Various Contraceptives

Method Progestin Estrogen Delivery route [Serum P] [LocalTissue P]
DMPA MPA 150mg None Injection 1-7 ng/mL Unknown
COCs Various EE Oral 1-6 ng/mL 0.2-3 ng/g*
LNG-IUD LNG None Intrauterine 0.1-0.4 ng/mL 1-5 ng/g
Cu-IUD None None Intrauterine n/a n/a
Net-En Norethindrone
enanthate 200mg		 None Injection 1-15ng/mL Unknown
CycloFem MPA 25mg E2C 5mg Injection 0.5-2 ng/mL Unknown
Jadelle Levonorgestrel None Subdermal 0.7-0.9 ng/mL Unknown
Nexplanon Etonogestrel None Subdermal 0.8-0.9ng/mL Unknown
NuvaRing Etonogestrel 11.7mg EE 2.7mg Intravaginal 1-2 ng/mL 0.2-1ng/g
OrthoEvra Norelgestromin 6mg EE 0.75mg Transdermal 0.3-1.5 ng/mL Unknown

MPA= medroxyprogesterone acetate; LNG= levonorgestrel; EE=ethinyl estrodiol; E2C=estradiol cypionate; Net-En-norethindrone enanthate

*

only available data for COCs: 150mcg/20mcg desogestrel/EE pill formulation

Note: the primary active metabolite of desogestrel is etonogestrel

NuvaRing: releases 150ug ENG and 15ug EE/day